1stOncology™: Cancer Intelligence Service – Page 6057 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Targovax ASA: Poster presentation at the AACR Annual Meeting

On March 9, 2022 Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, reported that an abstract has been accepted for poster presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting (Press release, Targovax, MAR 9, 2022, View Source [SID1234609747]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

The abstracts show ONCOS-102 drives pro-inflammatory modulation of the tumor micro-environment in PD-1 refractory melanoma tumors. ONCOS-102 is associated with efficient viral gene expression and strong, sustained activation of immune-related genes, which may be targets for future combinations of ONCOS-102 and immune-modulators beyond PD-1/PD-L1 inhibitors.

The abstract has been released on the AACR (Free AACR Whitepaper) website today (View Source). The poster is scheduled for presentation Monday 11 April 2022 and will be available on Targovax’s website after the presentation.

Poster title:

Modulation of immune gene expression by intra-tumoral oncolytic adenovirus ONCOS-102 is associated with clinical response in anti-PD-1 refractory/resistant melanoma

Date and time:

Monday 11 April 2022, 13:30- 17:00 CDT / 20:30-24:00 CET

Location:

New Orleans Convention Center, Exhibit Halls D-H, Poster Section 31

Session category:

Clinical research excluding trials

Session title:

Immune response to therapies / immune monitoring and clinical correlate

Poster number:

1983

Presenter:

Thomas Birkballe Hansen, VP Research, Targovax

About AACR (Free AACR Whitepaper)

The AACR (Free AACR Whitepaper) Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR (Free AACR Whitepaper) Annual Meeting highlights the work of the best minds in cancer research from institutions all over the world.

Onxeo’s new preclinical data confirm the relevance of combining AsiDNA™ with PARP inhibitors in treating homologous recombination proficient tumors

On March 9, 2022 Onxeo S.A. (Euronext Growth Paris: ALONX, First North Copenhagen: ONXEO), ("Onxeo" or "the Company"), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR), reported the presentation of new preclinical data confirming the relevance of combining AsiDNA with PARP inhibitors (PARPi) in homologous recombination repair (HRP) tumor models, during poster and oral sessions at the ESMO (Free ESMO Whitepaper) Targeted Anticancer Therapies Congress (7-8 March, 2022) (Press release, Onxeo, MAR 9, 2022, View Source [SID1234609746]).

Although PARP inhibitors have shown significant benefits in cancer patients with deficient homologous recombination repair (HRD), they show no or very limited efficacy in tumors with active or proficient homologous recombination repair (HRP). The data presented by Onxeo highlight the therapeutic opportunity of combining AsiDNA and PARPi in HRP tumors to overcome intrinsic or acquired resistance in clinical situation.

Wael Jdey, Preclinical Lead of Onxeo, stated: "The fact that PARP inhibitors showed limited efficacy in HRP tumors represents a significant unmet need, and addressing these aggressive tumors seems to be challenging. We already showed that AsiDNA disrupts the homologous recombination repair in different HRP tumor models, and therefore, induces a functional HRD that sensitizes HRP tumors to PARP inhibitors. This has been recently validated in preclinical HRP tumor models using more appropriate patient-friendly treatment schedules. Moreover, we also validated the AsiDNA-driven HRD in patient biopsies from DRIIV-1 clinical trial. These new data provide further evidence that our leading drug candidate shows high potential to drive synthetic lethality in combination with PARP inhibitors and reverses the relapse of aggressive tumors during treatment with PARP inhibitors. We are delighted to have had the opportunity to present these new data at the ESMO (Free ESMO Whitepaper)-TAT Congress and will continue to strengthen our understanding of AsiDNATM’s unique mechanism of action and further explore its capabilities in cancer treatment."

Imvax to Present New Data on Tumor-Derived Immunotherapy Platform at AACR Annual Meeting 2022

On March 9, 2022 Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, reported two poster presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022 in New Orleans, La., from April 8-13, 2022 (Press release, Imvax, MAR 9, 2022, View Source;utm_medium=rss&utm_campaign=imvax-to-present-new-data-on-tumor-derived-immunotherapy-platform-at-aacr-annual-meeting-2022 [SID1234609745]).

At the meeting, Imvax will present data that support the applicability of its platform to solid tumor types beyond glioblastoma. Using murine models of hepatocellular carcinoma and ovarian cancer, Imvax found that treatment with IHV-001 hepatocellular and IOV-001 ovarian immunotherapeutic products led to a significant improvement in survival and reduction in tumor burden of mice treated.

The company will also present analyses of new laboratory data from a Phase 1b clinical study using IGV-001 product candidate in newly diagnosed glioblastoma. That study had previously reported a median progression-free survival of 38.4 months in a subgroup of patients treated with IGV-001, compared with 8.3 months in historical standard-of-care-treated patients (P=0.0008) (Andrews et al., Clin. Canc. Res. 2021). In the new analysis, the company used serum profiling and machine learning classification to identify key cytokines that may be associated with patient outcome.

Details of the poster presentations are as follows:

Title: Personalized immunotherapeutic platform with evidence of clinical activity in glioblastoma (IGV-001) protects mice against other lethal solid tumor challenges
Number: 626
Timing: April 10, 2022, 1:30 p.m. – 5:00 p.m. CDT
Presenter: Mark Exley, Ph.D., Chief Scientific Officer

Title: Machine learning algorithm identifies key serum cytokines associated with evidence of clinical activity in patients treated with personalized immunotherapeutic platform (IGV-001)
Number: 2782
Timing: April 12, 2022, 9:00 a.m. – 12:30 p.m. CDT
Presenter: Mark Exley, Ph.D., Chief Scientific Officer

Cothera Bioscience has announced that the NMPA has approved a Phase II clinical trial of PC-002 for high-grade B-cell lymphoma

On March 8, 2022 Cothera Bioscience, the parent company of Percans Oncology, reported that it received approval from the National Medical Products Administration (NMPA) to conduct a Phase 2 clinical trial to test its targeted MYC mutation inhibitor PC-002 as a first-line or second-line treatment for drug-resistant or relapsed high-grade B-cell lymphoma (HGBCL) (Press release, Cothera Bioscience, MAR 8, 2022, View Source [SID1234618849]). The NMPA completed its review of the project in just 45 working days, demonstrating the strong support of regulatory authorities for innovative drugs.

PC-002, the core product of Cothera Bioscience, is a first-in-class small molecule drug targeting MYC-mutated tumors. With a unique mechanism of action (MOA), PC-002 selectively induces MYC protein degradation and cell apoptosis in MYC-dependent tumors. With more than 50% of human cancers showing increased expression, MYC is regarded as one of the most important yet "undruggable" cancer targets. Via its unique mechanism, PC-002 selectively kills tumor cells with MYC mutation and may potentially target multiple indications in cancers.

Bolt Biotherapeutics to Present Updates for Three Preclinical Immuno-Oncology Pipeline Programs at AACR Annual Meeting 2022

On March 8, 2022 Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology therapeutics that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, reported that it will present posters for three of the company’s preclinical pipeline programs at the upcoming American Association of Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022, being held in-person and virtually at the Ernest N. Morial Convention Center in New Orleans, LA from April 8-13, 2022 (Press release, Bolt Biotherapeutics, MAR 8, 2022, View Source [SID1234618689]).

"We are pleased to present three poster presentations at the AACR (Free AACR Whitepaper) Annual Meeting that highlight the significant progress made by our research team and the depth of our expertise in myeloid biology. We are continuing to expand our Boltbody ISAC platform with advanced CEA- and PD-L1-targeting ISACs, both of which have the potential to provide cancer patients with new options where few treatments are currently available. We are expanding our pipeline beyond ISACs through the development of our novel myeloid modulating antibody, BDC-3042, which repolarizes tumor-associated macrophages, or TAMs, into tumor destructive macrophages via agonism of Dectin-2," said Randall Schatzman, Ph.D., Chief Executive Officer of Bolt Biotherapeutics.

Three of Bolt Biotherapeutics’ preclinical programs will be featured in poster presentations: (1) BDC-2034, a CEA-targeting immune-stimulating antibody conjugate (ISAC) expected to enter clinical development in the second half of 2022, (2) BDC-3042, a Dectin-2-targeting, myeloid-modulating antibody anticipated to enter clinical development in 2023, and (3) a PD-L1-targeting ISAC. These posters will highlight updates on preclinical research for each of the programs, demonstrating anti-tumor activity and supporting future clinical development for all three programs.

Poster presentation sessions will be conducted in-person and available electronically on April 12 and 13 and will be published in Proceedings of the AACR (Free AACR Whitepaper). Details for each presentation can be seen below and on the AACR (Free AACR Whitepaper) website.

Title: The CEA-targeted ISAC, BDC-2034, shows preclinical efficacy associated with innate immune activation, phagocytosis, and myeloid reprogramming
Presenter: William G. Mallet, Ph.D.
Session Date and Time: Tuesday Apr 12, 2022, 9:00 a.m. – 12:30 p.m. CST
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 38
Poster Board Number: 26
Abstract Number: 2911

Title: Dectin-2 agonist antibodies reprogram tumor-associated macrophages to drive anti-tumor immunity
Presenter: Shelley Ackerman, Ph.D.
Session Date and Time: Tuesday Apr 12, 2022, 9:00 a.m. – 12:30 p.m. CST
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 37
Poster Board Number: 26
Abstract Number: 2883

Title: PD-L1-targeted ISAC combines myeloid cell activation, immune-checkpoint inhibition and ADCP to improve anti-tumor efficacy over anti-PD-L1 antibodies in preclinical models
Presenter: Justin Kenkel, Ph.D.
Session Date and Time: Wednesday Apr 13, 2022, 9:00 a.m. – 12:30 p.m. CST
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 39
Poster Board Number: 11
Abstract Number: 4252

About the Boltbody Immune-Stimulating Antibody Conjugate (ISAC) Platform
ISACs are a new category of immunotherapy that combines the precision of antibody targeting with the strength of the innate and adaptive immune systems. Boltbody ISACs comprise three primary components: a tumor-targeting antibody, a non-cleavable linker, and a proprietary immune stimulant to activate the patient’s innate immune system. By initially targeting a single marker on the surface of a patient’s tumor cells, an ISAC can create a new immune response by activating and recruiting myeloid cells. The activated myeloid cells start a feed-forward loop by releasing cytokines and chemokines, chemical signals that attract other immune cells and lower the activation threshold for an immune response. This reprograms the tumor microenvironment and invokes an adaptive immune response that targets the tumor, which can lead to the conversion of immunologically "cold" tumors to "hot" tumors with the goal of durable responses for patients with cancer.